Comparing SenesTech (SNES) and Its Rivals

SenesTech (NASDAQ: SNES) is one of 186 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its rivals? We will compare SenesTech to similar businesses based on the strength of its analyst recommendations, valuation, earnings, risk, dividends, profitability and institutional ownership.

Profitability

This table compares SenesTech and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SenesTech -14,473.40% -190.41% -150.12%
SenesTech Competitors -4,537.36% -502.02% -43.08%

Valuation and Earnings

This table compares SenesTech and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
SenesTech $320,000.00 -$10.79 million -0.65
SenesTech Competitors $207.03 million -$40.51 million -66.17

SenesTech’s rivals have higher revenue, but lower earnings than SenesTech. SenesTech is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

14.4% of SenesTech shares are owned by institutional investors. Comparatively, 49.1% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 27.4% of SenesTech shares are owned by company insiders. Comparatively, 14.9% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and price targets for SenesTech and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SenesTech 0 0 2 0 3.00
SenesTech Competitors 658 2462 6646 134 2.63

SenesTech presently has a consensus price target of $8.50, indicating a potential upside of 877.01%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 11.65%. Given SenesTech’s stronger consensus rating and higher possible upside, analysts plainly believe SenesTech is more favorable than its rivals.

Summary

SenesTech beats its rivals on 7 of the 12 factors compared.

About SenesTech

SenesTech, Inc. is a United States-based biotechnology platform and research company. The Company is engaged in developing a technology for managing animal populations by fertility control. It offers ContraPest, a fertility control product candidate. ContraPest’s technology and approach targets the reproductive capabilities of both sexes. Using bait stations, ContraPest is dispensed in a palatable liquid formulation that promotes sustained consumption by rodent communities. Its formulation causes both female and male rats to become infertile once they have consumed the dose. The active ingredient in females accelerates the rate at which ovarian follicles (egg structures) are depleted. Once these cells are gone, the animal cannot reproduce. In males, there is a marked reduction in the ability to fertilize eggs and, often complete sterility. ContraPest is designed, formulated and dispensed for handlers and non-target species, such as wildlife and pets in a biodegradable product.

Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply